New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, USA; Tulane University School of Medicine, New Orleans, USA; Louisiana State University School of Medicine, Section of Pulmonary Medicine, New Orleans, USA; University Medical Center - Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease Clinic Programs, New Orleans, USA.
Vanderbilt University Medical Center, Nashville, TN, USA.
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101707. doi: 10.1016/j.berh.2021.101707. Epub 2021 Sep 15.
Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.
系统性硬化症(SSc)是最致命的风湿性疾病,导致>50%的 SSc 病例死亡,其死亡原因主要为肺纤维化,其次为肺动脉高压,然后是硬皮病肾危象(SRC)。多种其他可预防和可治疗的 SSc 相关血管、心脏、胃肠道、营养和肌肉骨骼并发症可导致残疾和死亡。血管损伤随后发生炎症,转化为不可逆转的纤维化和永久性损伤,是 SSc 的特征。器官受累通常在 SSc 的疾病早期就存在,但需要仔细询问病史和警惕筛查以发现。只要治疗强度能抑制炎症和其他免疫机制,炎症就具有潜在的可逆性。在任何 SSc 表型中,早期治疗的机会都容易被低估,尤其是在进展缓慢的表型中,与严重进展性ILD 相反,ILD 缓慢进展,不可逆转地累积器官损伤,导致后期生命限制并发症,如肺动脉高压、心脏受累和营养不良。与其他风湿性或肺部疾病相比,单个 SSc 患者就诊通常需要医生和工作人员花费更多的时间、组织、警惕性和直接管理多个器官系统。综合 SSc 护理的效率和效果需要对症状和生物数据进行趋势分析。了解复杂患者的保险报销和卫生系统分配政策有助于 SSc 护理的财务可持续性。在认可的 SSc 中心和当地心脏病学/肺病学/风湿病学/胃肠病学同事之间共享护理可以预防并发症和不良结局,同时为当地专家提供支持。作为硬皮病专家,我们提供了一个实用的框架和工具,以促进 SSc 护理的最佳、全面和可持续方法。改善 SSc 的健康结果依赖于对 SSc 和治疗相关并发症的识别、管理和在可能的情况下预防。